Geode Capital Management’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-239,790
| Closed | -$8.13M | – | 4581 |
|
|
2025
Q4 | $8.13M | Buy |
239,790
+118,326
| +97% | +$3.67M | ﹤0.01% | 2507 |
|
|
2025
Q3 | $3.13M | Sell |
121,464
-18,595
| -13% | -$243K | ﹤0.01% | 3011 |
|
|
2025
Q2 | $1.12M | Sell |
140,059
-23,258
| -14% | -$177K | ﹤0.01% | 3290 |
|
|
2025
Q1 | $1.59M | Buy |
163,317
+73,700
| +82% | +$725K | ﹤0.01% | 3129 |
|
|
2024
Q4 | $1.13M | Buy |
89,617
+4,220
| +5% | +$53.6K | ﹤0.01% | 3328 |
|
|
2024
Q3 | $1.37M | Sell |
85,397
-192
| -0.2% | -$3.88K | ﹤0.01% | 3247 |
|
|
2024
Q2 | $2.09M | Buy |
85,589
+687
| +0.8% | +$31.7K | ﹤0.01% | 3116 |
|
|
2024
Q1 | $6.1M | Buy |
84,902
+1,240
| +1% | +$172K | ﹤0.01% | 2587 |
|
|
2023
Q4 | $16.6M | Buy |
83,662
+5,051
| +6% | +$625K | ﹤0.01% | 2025 |
|
|
2023
Q3 | $10.5M | Buy |
78,611
+10,617
| +16% | +$1.73M | ﹤0.01% | 2244 |
|
|
2023
Q2 | $10.2M | Buy |
67,994
+1,925
| +3% | +$300K | ﹤0.01% | 2277 |
|
|
2023
Q1 | $9.7M | Buy |
66,069
+9,206
| +16% | +$1.86M | ﹤0.01% | 2272 |
|
|
2022
Q4 | $9.01M | Buy |
56,863
+3,720
| +7% | +$595K | ﹤0.01% | 2337 |
|
|
2022
Q3 | $10.2M | Buy |
53,143
+2,339
| +5% | +$442K | ﹤0.01% | 2237 |
|
|
2022
Q2 | $7.42M | Buy |
50,804
+4,480
| +10% | +$597K | ﹤0.01% | 2460 |
|
|
2022
Q1 | $8.15M | Buy |
46,324
+3,322
| +8% | +$627K | ﹤0.01% | 2480 |
|
|
2021
Q4 | $12.6M | Sell |
43,002
-356
| -0.8% | -$95.2K | ﹤0.01% | 2286 |
|
|
2021
Q3 | $10.8M | Buy |
43,358
+14,909
| +52% | +$3.94M | ﹤0.01% | 2409 |
|
|
2021
Q2 | $7.24M | Buy |
28,449
+7,260
| +34% | +$1.36M | ﹤0.01% | 2687 |
|
|
2021
Q1 | $3.76M | Buy |
21,189
+3,192
| +18% | +$526K | ﹤0.01% | 2921 |
|
|
2020
Q4 | $2.84M | Buy |
17,997
+766
| +4% | +$167K | ﹤0.01% | 2890 |
|
|
2020
Q3 | $4.44M | Buy |
17,231
+806
| +5% | +$179K | ﹤0.01% | 2460 |
|
|
2020
Q2 | $3.81M | Buy |
16,425
+7,606
| +86% | +$1.18M | ﹤0.01% | 2494 |
|
|
2020
Q1 | $1.5M | Buy |
8,819
+5,121
| +138% | +$1.17M | ﹤0.01% | 2823 |
|
|
2019
Q4 | $816K | Buy |
+3,698
| New | +$681K | ﹤0.01% | 3347 |
|
Geode Capital Management's RAPT Position: Q1 2026 in Review
Geode Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 239,790 shares — an estimated $8.13M sold.
Geode Capital Management first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $16.6M in Q4 2023. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Geode Capital Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Geode Capital Management sold 239,790 RAPT Therapeutics shares in Q1 2026, an estimated $8.13M.
- Geode Capital Management first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- Geode Capital Management's RAPT Therapeutics position peaked at $16.6M in Q4 2023.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.